D. Ross Camidge

His humble description of his own evolution from bench scientist to biotech ceo and the Highs and Lows of the journey is a delight to listen to.

Tim was known as the boy wonder when we were PhD students. Partly from his boyish looks but largely for his brilliance. How many PhDs contribute to a Nobel Prize? Then that experience of embracing science and industry led him to biotech

How an Interest in Scientific Intricacies Evolved to Transform the Biotechnology Field: With D. Ross Camidge, MD, PhD; and Tim Clackson, PhD Podcast Episode · How This Is Building Me · March 4 · 1h 5m

How This is Building Me - recently live: Me and Clackson. podcasts.apple.com/us/podcast/h...

Everyday Magic: on the walk back from the library yesterday I came across a fairy village. What I love most about this is both the person who built this and also the respect it has been given by passersby. No theft, no vandalism. Just shared magic.

YouTube video by IASLC IASLC 2026 IASLC Targeted Therapies of Lung Cancer: Special Presentation by Dr. Ross Camidge

@drcamidge.bsky.social’s incredible presentation from #TTLC26 is now available online. Anyone who deals with cancer in any capacity should watch it. You might cry (I did) but it’s worth it. Thank you IASLC for making the presentation publicly available.

m.youtube.com/watch?v=cnh5...

Thanks so much Tara. Agree the truths are larger than the specifics. We all want to just put one foot in front of another. Illness doesn’t change that, only the effort required

Strange bedfellows: After a year of fighting like their namesakes, Atticus and Cleo found a cold evening and a warm fire can bring anyone together.

Science Will Win Science Will Win is a podcast that takes listeners under the microscope on some of the most promising medical innovations, exploring therapies that have the potential to shape the future of healthcare...

Science Will Win podcast (live today) explains personalized medicine. I was their guest as example and expert at the same time 😀 link.podtrac.com/whifmgc8

I was so glad it was Shirish to introduce me and to ‘catch me’ at the end for what was an emotionally hard presentation- full vulnerability. He has been an amazing friend over the years

At last week’s lung cancer conference I went full public with my dual role as patient and expert. I spoke after Jane Perlmutter a four time survivor (middle). Both of us were introduced by Dr Shirish Gadgeel- Jane’s doctor and my friend.

The U Colorado lung medical oncology team as from today at the Targeted Therapies of Lung Cancer meeting in California.

I’d never cried at a conference until today. Ross, thank you for this incredible talk. You’re a wonderful human, clinician, researcher, boss, mentor, and friend. The standing ovation was more than deserved. @drcamidge.bsky.social @cucancercenter.bsky.social #TTLC26

Try, fail, try better, fail better. This is someone whose need to be a scientist is as much undeniable as a dancer to dance or a singer to sing.

I interviewed Sophia Merajver knowing her drive for science. But when I tracked her journey from her blind chess playing father, antisemitism, military juntas, growing up on the street that never sleeps in Buenos Aires to the USA I got new insights.

How Physics, Medicine, and Lived Experience Shaped a Career in Breast Cancer Research and Risk Evaluation: With Ross Camidge, MD; and Sofia Diana Merajver, MD, PhD Podcast Episode · How This Is Building Me · 02/04/2026 · 59m

Recently live: HTIBM Me and Merajver. podcasts.apple.com/us/podcast/h...

EGFR not yet explored in ALK etc but working on it

A new day, a new treatment. After some pleural progression it’s time to shake up the treatment paradigm. This time a single patient trial of an experimental drug that I helped develop (in fact the paper describing it is by Camidge et al and still in press in a major journal)

I had to look it up, but thank you for the education! 😀

The tail on the coffee grinder curve: After 20 seconds of pulverizing some beans survive intact. Hope in a French Press

The joy of new adventures 😀

On a trip to Chicago to work with AbbVie I got to try traveling with an implanted port for the first time. In the way out I declared my new upgrade and made intimate friends with the TSA officer. In the way back I just went through the metal detector as normal and nothing abnormal happened!

Hiding in Plain Sight: The Neuro-Protective Benefit of Tropomyosin Receptor Kinase Inhibition in Non-Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers - PubMed Hiding in Plain Sight: The Neuro-Protective Benefit of Tropomyosin Receptor Kinase Inhibition in Non-Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers

And now with spelling mistakes corrected! pubmed.ncbi.nlm.nih.gov/41563233/

How is the little guy?

A busy few days with minor medical tidy ups. After 3.5 years of scans with contrast my once tubular veins now need help. Ironman-like port now inserted. The upgrade was fascinating, as most medical things once ordered now experienced have been.

Listening to Justin makes we wish that all doctors were driven in the same way. He’s a fantastic example of ethical progress in oncology

Dr Justin Call went from community medical oncology practice to building a community phase I drug development program. Not a trials machine eating patients but a personalized, integrated addition to his Utah patients treatment when most appropriate.

How Community Oncology Experience Built the Foundation for a Dedicated Phase 1 Research Program: With D. Ross Camidge, MD, PhD; and Justin Call, MD Podcast Episode · How This Is Building Me · 01/21/2026 · 1h 13m

HTIBM Recently live: Me and Call. podcasts.apple.com/us/podcast/h...

In essence, Drugs that by chance inhibit TRK are hypothesized, based on breast cancer lab data and lung cancer clinical data, to stop deposits of cancer establishing themselves in the brain. If lung cancer lab data confirm then the potential to change oncology for the better across tumors is huge.

It’s a visionary or misguided idea depending on how more lab data and more clinical data shake out

Hiding in Plain Sight: The Neuro-Protective Benefit of Tyrosine Kinase Inhibition in Non–Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers

www.sciencedirect.com/science/arti... Now in press in Journal of Thoracic Oncology - a hypothesis I’ve presented at meetings for a couple of years but never put in writing before.